Background: Chemokine signaling through CCR3 is a key regulatory pathway for eosinophil recruitment into tissues associated with allergic inflammation and asthma. To date, none of the CCR3 antagonists have shown efficacy in clinical trials. One reason might be their unbiased mode of inhibition that prevents receptor internalization, leading to drug tolerance. Objective: We sought to develop a novel peptide nanoparticle CCR3 inhibitor (R321) with a biased mode of inhibition that would block G protein signaling but enable or promote receptor internalization. Methods: Self-assembly of R321 peptide into nanoparticles and peptide binding to CCR3 were analyzed by means of dynamic light scattering and nuclear magnetic resonance. Inhibitory activity on CCR3 signaling was assessed in vitro by using flow cytometry, confocal microscopy, and Western blot analysis in a CCR3
In patients with allergic disorders, such as asthma and eosinophilic esophagitis, eosinophils are recruited into the lung and esophagus, respectively, and activated in excess at these sites of inflammation. In patients with these diseases, eosinophils are both a histologic hallmark and among the major effector cell types contributing to their pathology. 1, 2 The CCR3 signaling pathway is one of the key regulatory pathways involved in eosinophil recruitment and migration into the affected tissues as part of the allergic diathesis.
Although CCR3 is most highly expressed by eosinophils, it is also expressed by basophils, subsets of mast cells and T H 2 cells, and airway epithelial cells. [3] [4] [5] CCR3 is a promiscuous G proteincoupled receptor (GPCR) interacting with multiple inflammatory chemokines, including the high affinity agonists eotaxin-1 (CCL11), eotaxin-2 (CCL24), eotaxin-3 (CCL26), and RANTES (CCL5). The receptor is coupled to the pertussis toxin-sensitive G protein Gai. On ligand binding, the receptor is activated, and active guanosine triphosphate (GTP)-bound Gai and the Gbg dimer dissociate from CCR3 to trigger downstream signaling cascades, including mitogen-activated protein kinase (extracellular signal-regulated kinase [ERK] 1/2 and p38) and the phosphoinositide 3-kinase/AKT pathways. 6, 7 These intracellular signaling pathways culminate in priming, chemotaxis, activation, and degranulation of eosinophils.
After receptor activation by the ligand, CCR3 is desensitized and internalized. 8, 9 The mechanism of CCR3 internalization is not yet fully understood but is thought to occur through b-arrestin recruitment to phosphorylated CCR3 and sequestration of the receptor into endosomes. 10 In addition, eotaxin-induced CCR3 internalization might be required for actin polymerization and chemotaxis. 9 The importance of CCR3 as a potential therapeutic target was established through observations that CCR3-null mice and eotaxin-1 and eotaxin-2 double-knockout mice displayed nearcomplete abolishment (up to approximately 70%) of allergeninduced airway eosinophil recruitment.
11 CCR3 transcript and protein levels are increased in the bronchial mucosa of patients with allergic asthma. 12 In line with this, much effort has been invested in the development of small-molecule CCR3 antagonists, yet none have been approved for clinical use to date. 4 Most of the currently known CCR3 antagonists are competitive or allosteric inhibitors of CCR3 activation and internalization by chemokines. 4 The dual-inhibitory activity of these molecules classifies them as unbiased antagonists. Reports on the use of unbiased antagonists of other GPCRs, such as CXCR4, suggest that after prolonged exposure, cell-surface GPCR accumulates, a phenomenon associated with developing resistance to receptor inhibition. 13, 14 These findings prompted us to search for antagonists that can ''bias'' downstream signaling by selectively inhibiting only one of the signaling cascades. There is a growing interest in the development of biased agonists of GPCRs, 15 but biased antagonists of GPCRs remain largely unexplored, very few have been identified, and their therapeutic potential remains to be determined.
In the present study we report the development and validation of R321, a novel peptide inhibitor derived from the second transmembrane helix of CCR3. R321 self-assembles into uniform nanoparticles and inhibits CCR3-mediated chemotaxis of human blood eosinophils with nanomolar potencies. Intravenously administered R321 significantly reduces eosinophil recruitment into the lung and airspaces and diminishes airway hyperresponsiveness (AHR) in a triple-allergen (dust mite, ragweed, and Aspergillus species [DRA]) mouse asthma model of allergic airway inflammation. We propose that the R321 peptide exerts its receptor inhibitory effects on eosinophil function as a biased antagonist by inhibiting G protein-mediated processes and promoting internalization (endocytosis) and degradation of CCR3.
METHODS Reagents
The small-molecule CCR3 antagonists SB238437 and UCB35625 were purchased from Tocris Bioscience (Bristol, United Kingdom).
Peptide synthesis and characterization
Synthesis, purification, and evaluation of nanoparticle formation of R321 and R323 peptides were performed as described in the Methods section in this article's Online Repository at www.jacionline.org.
Cell culture
AML14.3D10-CCR3 cells, an eosinophil-differentiated acute myeloid leukemia cell line stably transfected to express CCR3 (ATCC CRL-12079), were cultured, as previously described. 16 Jurkat cells, a T-cell leukemia line endogenously expressing CXCR4 but not CCR3, were cultured in RPMI-1640 supplemented with 10% FBS, 1% penicillin-streptomycin, and 2 mmol/L L-glutamine.
Eosinophil purification
Eosinophils were purified from blood drawn from patients with mild allergic asthma. Peripheral blood was separated over a gradient of FicollPaque Plus (GE Healthcare, Pittsburg, Pa). Eosinophils were further purified by means of negative selection with a commercial eosinophil isolation kit (MAC Miltenyi Biotec, Auburn, Calif).
Chemotaxis and degranulation assays
Chemotaxis and degranulation assays are described in the Methods section in this article's Online Repository.
Prolonged exposure to inhibitors
AML14.3D10-CCR3 cells or human peripheral blood eosinophils were incubated for 24, 48, or 72 hours with either vehicle control or 1 mmol/L inhibitors. Cells were resuspended in fresh complete medium with inhibitors every day.
Signal transduction: Western blotting and confocal microscopy
Detailed descriptions are provided in the Methods section in this article's Online Repository.
Receptor expression and internalization
Cells were treated for 30 minutes with vehicle control, R321 (0.01-10 mmol/L) with or without CCL11 (12 nmol/L), or R323, SB238437, and UCB35625 (all at 1 mmol/L) with or without CCL11 (12 nmol/L) to evaluate CCR3 cell-surface expression and ligand-induced internalization. Cells were blocked with 10% heat-inactivated human AB serum, stained with phycoerythrin (PE)-conjugated anti-human CCR3 antibody (clone 5E8; BioLegend, San Diego, Calif) or PE-conjugated isotype-matched control (BioLegend), and analyzed on a Quanta SC flow cytometer (Beckman Coulter, Indianapolis, Ind). The cell-surface staining and gating strategy used for enumeration of mouse blood eosinophils and determination of CCR3 surface expression levels is described in the Methods section in this article's Online Repository.
Mice
Female BALB/cJ mice (10-12 weeks of age) were purchased from the Jackson Laboratory (Bar Harbor, Me). All animal study protocols were reviewed and approved by the Institutional Animal Care and Use Committee of the University of Illinois (Chicago, Ill).
Sensitization and airway challenge
Sensitization and intranasal challenge were performed according to the acute asthma protocol previously described by Goplen at al. 17 In brief, mice were sensitized twice intraperitoneally with a cocktail of 3 allergens: dust mite (Dermatophagoides farinae), 5 mg; ragweed (Ambrosia artemisiifolia), 50 mg; and Aspergillus fumigatus, 5 mg. All extracts were purchased from Greer Laboratories (Lenoir, NC). One week after the second sensitization, intranasal challenges consisting of 0.15 mg of Aspergillus species, 0.15 mg of dust mite, and FIG 1. The R321 CCR3 peptide and its scrambled control (R323) self-assemble into nanoparticles. A, Structures of R321 and the scrambled peptide R323. Alignment with human and mouse CCR3 shows a high degree of identity at the TM2 region. B, DLS regularization distribution histograms are shown for 10 mmol/L peptide solutions in PBS. Radii for R321 and R323 are 7.1 6 0.7 and 4.5 6 0.4 nm, respectively, with R323 being somewhat smaller and more polydisperse; the polydispersity indices of R321 and R323 were 0.07 and 0.28, respectively. Results represent means 6 SEMs from experiments (n 5 3) performed in duplicates. C, R321 self-assembly into nanoparticles shows no dependence on peptide concentration. ECL, Extracellular loop; TM, transmembrane.
1.5 mg of ragweed extract were given for 3 consecutive days. Control mice were sham challenged with PBS. For the prophylactic protocol, R321, scrambled R323 peptide control, vehicle, or PBS was delivered by means of intravenous injection into the retro-orbital sinus 1 day before the first challenge and directly before each subsequent challenge. For the therapeutic protocol, mice started receiving 12 mg/kg R321 or R323 on the day after the final allergen challenge and for 3 additional days after the date of the last challenge.
Bronchoalveolar lavage, lung histology, and airway responsiveness to methacholine Bronchoalveolar lavage (BAL) was performed, as described in the Methods section in this article's Online Repository. Whole lungs were fixed in 10% formalin and embedded in paraffin. Lung tissue sections were stained with rat anti-mouse MBP1 antibody (generously provided by the Lee Laboratories, Mayo Clinic, Scottsdale, Ariz), as previously described. 18 Immunostained slides were scanned with the Aperio Scanscope CS2 scanner (Aperio, Vista, Calif) and analyzed with Aperio's image viewer software. Nuclei were counterstained with Mayer hematoxylin, and cell counts were expressed as percentages of MBP1 1 cells of total nucleated cell counts. Determination of airway responsiveness to methacholine is described in the Methods section in this article's Online Repository. Nuclear magnetic resonance (NMR) was performed as described in the Methods section in this article's Online Repository.
Statistical analysis
Statistical analysis was performed with 2-tailed t-tests or 1-way or 2-way ANOVA, followed by Tukey post hoc analysis in GraphPad Prism software (GraphPad Software, San Diego, Calif). (Fig 2, A) and AML14.3D10-CCR3 cells (Fig 2, B) . C, IC 50 /IC 90 inhibitory activity of the R321 peptide on eotaxin-induced chemotaxis of blood eosinophils and AML14.3D10-CCR3 cells. D, The scrambled peptide control R323 (1 mmol/L) does not significantly inhibit chemotaxis of blood eosinophils. In contrast, R321 inhibits chemotaxis by more than 90% when tested at the same (1 mmol/L) concentration. E, R321 does not inhibit CXCL12/CXCR4-mediated chemotaxis of Jurkat-T lymphocyte leukemia cells. Results are normalized to the percentage of maximum chemotactic response and are representative of means 6 SEMs from experiments (n 5 3) performed in triplicate. ns, P > .05.
RESULTS

R321 self-assembles into nanoparticles
Peptides containing sequences from each of the 7-transmembrane domains and associated extracellular loops of human CCR3 were first screened for inhibition of chemotaxis to CCL11, identifying the second transmembrane domain and first extracellular loop region as the most inhibitory (data not shown). The final design of R321 (Fig 1, A) was based on a previously described self-assembling CXCR4 peptide antagonist. 19, 20 Twenty-seven units of polyethylene glycol (PEG) were placed on the C-terminus of the peptide to prevent aggregation, and the PEG units were followed by 3 aspartate residues that ensure homogeneous self-assembly and correct orientation on membrane fusion (Fig 1, A) . The control peptide R323 was derived by randomly but separately scrambling the sequences of the R321 transmembrane and extracellular loop regions (Fig 1, A) . Dynamic light scattering (DLS) analysis (Fig 1, B) showed that R321 and R323 monomers both self-assemble in an aqueous environment into nanospheres with a hydrodynamic radius of 7.1 6 0.7 and 4.5 6 0.4 nm, respectively, with R323 being smaller and more polydisperse than R321. The size of the R321 particles was maintained over a wide range of monomeric concentrations (Fig 1, C) .
R321 specifically inhibits eotaxin-induced eosinophil chemotaxis
Human blood eosinophils and the stable CCR3 1 eosinophilic myelocyte cell line AML14.3D10-CCR3 undergo CCR3-mediated chemotaxis induced by multiple chemokines, including CCL11/eotaxin-1, CCL24/eotaxin-2, and CCL26/eotaxin-3 (Fig 2) . R321 was observed to inhibit eotaxin-induced chemotaxis by both primary eosinophils (Fig 2, A) and the AML14.3D10-CCR3 cell line (Fig 2, B) in a dose-dependent manner and with nanomolar potencies. Half-maximal inhibitory concentration (IC 50 ) and 90% inhibitory concentration (IC 90 ) values are shown in Fig 2, C . When used at a concentration of 1 mmol/L (approximate IC 90 value for R321), the scrambled peptide control (R323) did not significantly inhibit eotaxin-mediated chemotaxis in blood eosinophils (Fig 2, D) . R321 did not inhibit CXCR4-mediated chemotaxis in Jurkat T cells (Fig 2, E) and platelet-activating factor (PAF)-mediated chemotaxis of blood eosinophils (see Fig E1 in Effects of R321 on CCR3 signal transduction pathways R321 was found to inhibit activation of Gai in an immunoprecipitation assay that detects Gai-GTP (Fig 3, A) but did not inhibit receptor degradation (Fig 3, B) . Pretreatment of AML14.3D10-CCR3 cells with 10 mmol/L R321 (a concentration exceeding IC 50 and IC 90 for chemotaxis) before ligand exposure was even found to enhance degradation of the CCR3 receptor (Fig  3, B) . Both G protein-and b-arrestin-mediated signaling pathways can lead to AKT and ERK1/2 activation, although the time course of activation through the 2 pathways is different, leading to biphasic phosphorylation. [22] [23] [24] [25] After stimulation of AML14.3D10-CCR3 cells with chemokines, biphasic phosphorylation of AKT (Fig 3, C) and ERK1/2 (Fig 4, A) was observed in Western blots. Early (2-5 minutes) phosphorylation is mediated by G protein signaling. Sustained late-phase (30 minutes) phosphorylation is likely due to b-arrestin signaling, as demonstrated for other GPCRs. 22, 25, 26 Pretreatment of cells for 30 minutes with 10 mmol/L R321 before stimulation led to complete inhibition of the early phase of ERK1/2 activation (5 minutes) but had no effect on the prolonged late phase (30 minutes). The control peptide R323 had no effect on ERK1/2 phosphorylation patterns. Both SB328437 and UCB35625 fully inhibited the late phase, with SB328437 blocking the early phase as well and UCB35625 doing so only partially (Fig 4, A) . These results indicate that, unlike SB328437 and UCB35625, R321 does not inhibit the b-arrestin signaling that mediates the late-phase phosphorylation of ERK1/2.
R321 does not antagonize b-arrestin recruitment to CCR3
Colocalization of CCR3 and b-arrestin 2 was observed after stimulation of CCR3 with CCL11 (Fig 4, B) , suggesting that b-arrestin plays a role in ligand-induced CCR3 internalization and Active GTP-bound Gai was immunoprecipitated (IP) by using antibody specific for Gai GTP and detected by using Western blotting (WB) with antibody to total Gai. Input lysates were blotted for CCR3 as a loading control. B, R321 does not inhibit b-arrestin signaling by activated CCR3. AML14.3D10-CCR3 cells were treated with CCL11 (12 nmol/L) or RANTES/ CCL5 (12 nmol/L) for 3 hours. Decrease in CCR3 levels indicates receptor degradation after exposure to ligand. Pretreatment with 10 mmol/L R321 before CCR3 ligands enhances degradation. GAPDH, Glyceraldehyde-3-phosphate dehydrogenase. C, Eotaxin-mediated activation of CCR3 leads to biphasic activation of AKT. After CCR3 activation by the indicated chemokines (12 nmol/L), biphasic phosphorylation of AKT was observed. Acute (2-minute) phosphorylation is mediated by G protein signaling. Late-phase (30 minutes) phosphorylation is likely due to b-arrestin signaling.
degradation. Pretreatment of cells with 10 mmol/L R321 or R323 did not significantly (P > .05) alter the reported colocalization coefficients either before or after CCL11 stimulation (Fig 4, C) . In contrast, colocalization of CCR3 and b-arrestin 2 was significantly attenuated after treatment with UCB35625 and SB328437 when compared with untreated cells (P < _ .0001; 
R321 promotes rather than inhibits CCR3 internalization and degradation
Inhibition of b-arrestin signaling can interfere with effective degradation of CCR3 and lead to receptor accumulation on the eosinophil cell surface. Surface levels of CCR3 in AML14.3D10-CCR3 cells were determined by using flow cytometry to elucidate the fate of CCR3 on ligand and inhibitor treatment. More than 50% of CCR3 present on the cell surface was internalized after 30 minutes of CCL11 exposure, which is in keeping with previous reports. 8, 27 R321 and the scrambled R321 peptide control showed no significant effect on ligand-induced receptor internalization, whereas the small-molecule antagonists UCB35625 and SB328437 partially blocked CCR3 internalization and degradation (Fig 5, A) . Of note, R321 at 10 mmol/L was found to promote CCR3 internalization on its own, without the addition of chemokine ligand (Fig 5, B) .
R321 maintains its efficacy over 72 hours in contrast to unbiased antagonists
The effects of prolonged exposure to inhibitors on CCL11-induced chemotaxis and CCR3 surface expression was assessed for up to 72 hours in AML14.3D10-CCR3 cells and blood eosinophils (Fig 5, C and D) . CCL11 (12 nmol/L) alone and CCL11 plus R321 reduced CCR3 expression to approximately 68% and 55%, respectively, after 24 hours and to approximately 18% and 12%, respectively, after 72 hours (Fig 5, D) . Treatment of cells for 72 hours with R321 alone reduced surface levels of CCR3 to 68% compared with untreated cells. In contrast, UCB35625 leads to receptor accumulation on the surface and enhanced CCR3 surface levels up to 133% after 72 hours. R323 and SB328437 had no significant effect on receptor levels. A similar effect was observed on CCR3 surface expression in AML14.3D10-CCR3 cells (see Fig A, After CCR3 activation with 100 nmol/L CCL11, biphasic ERK1/2 phosphorylation was observed. Acute (2-5 minutes) phosphorylation is mediated by G protein signaling. Late-phase (30 minutes) phosphorylation is likely due to b-arrestin signaling. R321 (10 mmol/L) inhibits only acute phosphorylation of ERK1/2. The scrambled peptide control R323 (10 mmol/L) does not inhibit acute or late-phase phosphorylation. SB328437 (10 mmol/L) inhibits both acute and late-phase phosphorylation, and UCB35625 (10 mmol/L) inhibits the late phase to a higher degree than the early phase. B, Representative confocal images of AML14.3D10-CCR3 cells exposed to vehicle or inhibitors for 30 minutes and stimulated with CCL11/ eotaxin-1 for 30 minutes. DAPI, 49-6-Diamidino-2-phenylindole dihydrochloride. C, Quantitation by using the Pearson correlation method shows colocalization of CCR3 to b-arrestin 2 thirty minutes after stimulation with CCL11/eotaxin-1. R321 and R323 (10 mmol/L) did not inhibit CCL11-induced b-arrestin 2 recruitment to CCR3, whereas the CCR3 antagonist SB328437 and UCB35625 strongly inhibited colocalization. Results represent means (50 cells per treatment group) 6 SEMs from 3 independent experiments. *P < _ .05, **P < _ .01, and ****P < _ .0001 compared with control values.
of chemotaxis), whereas UCB35625 and SB328437 inhibition levels decreased by 19.3% and 13.7%, respectively (Fig 5, C) . These results indicate that resistance to the small-molecule inhibitors, but not to R321, develops over time.
R321 inhibits eosinophil recruitment into the lungs and airspaces
In a robust mouse DRA allergic asthma model of eosinophilic airway inflammation (Fig 6, A) , prophylactically (see Fig E5, A, in this article's Online Repository at www.jacionline.org) administered intravenous R321 demonstrated a dose-dependent inhibitory effect on eosinophil recruitment into the airways (Fig 6, B) . Significantly, R321 reduced eosinophil counts in the bronchoalveolar lavage fluid beginning at a dose of 6 mg/kg (44.24% 6 9.33% of vehicle) and reached 69.33% 6 4.20% inhibition at the maximum dose of 12 mg/kg (Fig 6, C) . An IC 50 value of 8.16 mg/kg was obtained from linear regression analysis. R323 showed no inhibitory effect at 12 mg/kg. No significant differences were observed in total counts of other inflammatory cells, including macrophages, neutrophils, or lymphocytes (see Fig E6 in this article's Online Repository at www.jacionline.org). MBP1-stained lung tissues showed a 36.20% 6 5.28% decrease in eosinophil counts after treatment with 12 mg/kg R321 (Fig 6,  D) . In a therapeutic protocol (see Fig E5, B) , R321 (12 mg/kg) successfully reduced airway (BAL) eosinophils by 74.18% 6 6.50% (Fig 7, A) and lung eosinophils by 83.30% 6 7.29%, fully reversing allergen-induced eosinophilia in both the blood (Fig 7,  B) and lung tissue (Fig 7, C and E) to levels comparable with those in PBS-sham-challenged mice. As expected, blood eosinophils (Fig 5, B and D) or the 24-hour data point (Fig 5, C ): *P < _ .05, **P < _ .01, ***P < .001, and ****P < _ .0001. ns, Not significant. Error bars 5 SEMs.
displayed reduced levels of surface CCR3 on exposure to allergen when compared with sham-challenged control cells (approximately 29% reduction; Fig 7, D) , and R321 treatment further reduced CCR3 levels (approximately 15% reduction compared with vehicle, P 5 .01). The protocols for allergen (DRA) sensitization, airway challenge, and peptide treatments are shown in Fig E5. R321 blocks AHR in allergen-challenged mice DRA-challenged mice had an approximately 9 times higher peak system and airway resistance in response to methacholine compared with sham-challenged (PBS) mice (Fig 6, E and F) . R321 treatment had a striking effect on airway responsiveness, reducing both the system and airway pulmonary resistance of challenged mice to levels comparable with those observed in sham-challenged (PBS) mice.
R321 interacts with CCR3 and allows chemokine binding
To study binding of R321 to CCR3, we used NMR spectroscopy to correlate with total nucleated cells. Means 6 SEMs are shown for 6 to 7 mice per treatment group from 3 independent experiments. E and F, R321 at 12 mg/kg significantly decreases respiratory system (Fig 6, E) and airway ( Fig  6, F) responsiveness to methacholine compared with vehicle or R323 controls. There is no significant difference between R321-treated and sham-challenged mice (n 5 5: except PBS group, n 5 4). *P < .05, **P < .01, ***P < .001, and ****P < .0001. ns, Not significant.
in this article's Online Repository at www.jacionline.org).
28-33
The heteronuclear single quantum coherence (HSQC) spectrum of CCR3 1 membranes contained 4 discernable signals (Fig 8,  A) . In contrast, CCR3-null membrane exhibited only 2 signals (Fig 8, A) . These signals overlapped with only 2 of 4 signals of CCR3 1 membranes, suggesting that the remaining 2 signals belong to CCR3 (Fig 8, A) . Immunoblotting only detected CCR3 in the CCR3 1 membranes (see Fig E8 in this article's Online Repository at www.jacionline.org). Moreover, CCL11 specifically reduced the intensity of CCR3 signals (Fig 8, B , black arrows) but did not affect the spectrum of CCR3-null membranes (see Fig E8) . Similar to CCL11, R321 shifted only the CCR3 signals (Fig 8, C) . This suggests that R321 specifically perturbs CCR3 structure. reduced on allergen challenge. R321 does not inhibit CCR3 internalization but has a promoting effect (vehicle group median fluorescence intensity [MFI] of 13.7 versus R321-treated group MFI of 11.7, P 5 .01). The mean 6 SEM is shown for 5 mice per treatment group. *P < .05, **P < .01, ***P < .001, and ****P < .0001. ns, Not significant. E, Representative images of mouse lung airways (top) and blood vessels (bottom) from Fig 7 , C, immunostained with horseradish peroxidase-conjugated antibodies to MBP1 (positive cells are dark brown). Black bars 5 100 mm.
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Next, we investigated the interaction of R321 and CCR3 in the presence of CCL11 (Fig 8, D-F) . The chemical shift changes and differences in signal intensities show that neither CCL11 nor R321 interfere with the other's binding to the receptor. This suggests that R321 and CCL11 interact with CCR3 simultaneously and R321 alters CCL11's ability to activate signaling (Fig 8) .
Dose-dependent responses of CCR3 at different concentrations of R321 (see Figs E7 and E9 in this article's Online Repository at www.jacionline.org) allowed calculation of dissociation constants (see Fig E7, C) . We found 2 dissociation constants for R321 binding to the receptor, one in the nanomolar range and the other in the micromolar range. This suggests that R321 might use 2 distinct mechanisms for interaction with CCR3, potentially explaining its unique inhibitory profiles in vitro and in vivo.
DISCUSSION
In the present study we report the development and characterization of a novel peptide inhibitor of CCR3. The described peptide (R321) self-assembles into uniformly sized nanoparticles, essentially functioning as its own carrier and delivery system. Self-assembly protects the peptide from proteolytic degradation, a known issue with peptide-based drugs. 20 Addition of PEG to the R321 nanoparticles is recognized to further prevent aggregation and proteolytic degradation, improve pharmacokinetics, and reduce the immunogenicity of peptide-based drugs. 34 In this study intravenous administration was used as the most reliable method for delivering R321 peptide nanoparticles to the systemic circulation. However, future studies will involve alternate routes of administration, notably formulating R321 preparations for nebulization or direct airway instillation or inhalation. UCB35625, which was initially identified as a highaffinity unbiased antagonist of CCR3 and CCR1, was found subsequently to be an agonist of CCR2 and CCR5, making it prohibitively complex for in vivo studies. 35, 36 SB328437 was developed as a specific inhibitor of CCR3 in eosinophils and was shown to successfully suppress OVA-induced accumulation of eosinophils in the lungs of mice adoptively transferred with in vitro-differentiated T H 2 cells. 37, 38 However, a very high subcutaneous dose (100 mg/kg) of SB328437 resuspended with Tween-80 was used in the study, and we have also experienced solubility issues with this compound, making it unsuitable for intravenous injection.
CCR3 signaling is implicated increasingly in various pathologic contexts besides allergic inflammation. These include agerelated macular degeneration, 39 reproductive malignancies, [40] [41] [42] eosinophilic myocarditis, 43 neurodegenerative diseases, 44 renal cell carcinoma, 45 Crohn disease, 46 and glioblastoma. 47 Several antagonists that prevent chemokine binding to CCR3 have been developed; however, none of these inhibitors have been US Food and Drug Administration approved. Failures of smallmolecule CCR3 inhibitors in the few clinical trials that have FIG 8 . R321 binds CCR3 in the plasma membrane in the presence of CCL11. 13 C HSQC spectra of 13 C reductively methylated CCR3-positive and CCR3-null membranes were recorded with or without 1 mmol/L CCL11 in the presence or absence of 2 mmol/L R321. Spectral comparisons between (A) CCR3 (CCR3-K-di 13 CH 3 ; red) and CCR3-null membranes (blue; A), CCR3 alone (CCR3-K-di 13 CH 3 ; red) and CCR3 plus CCL11 (blue; B), CCR3 alone (CCR3-K-di 13 CH 3 ; red) and CCR3 plus R321 (blue; C), CCR3 alone (CCR3-K-di 13 CH 3 ; red) and CCR3 plus CCL11 and R321 (blue; D), CCR3 plus CCL11 (red) and CCR3 plus CCL11 and R321 (blue; E), and CCR3 plus R321 (red) and CCR3 plus CCL11 and R321 (blue; F) show line broadening and chemical shift changes indicative of binding. Black arrows show significant changes in CCR3-associated signals but not in signals that belong to other membrane proteins.
been conducted have called into question the role of CCR3 in airway eosinophilia in asthmatic patients, suggesting that CCR3 is not a viable target for drug development. However, a clinical trial of the unbiased CCR3 antagonist GW766994 showed a trend toward inhibition of sputum eosinophils, with significant inhibition of AHR, 48 suggesting treatment duration might not have been sufficient to meet primary study end points 48, 49 or that eosinophils and other CCR3 1 target cells developed resistance (tolerance) to this unbiased antagonist.
Furthermore, studies have shown that CCR3 knockout mice display up to a maximum of 70% reduction in eosinophil recruitment into the airways in an OVA-asthma model. 50 In agreement with this finding, our in vivo results from the mouse DRAasthma model also validate CCR3 as a drug target because the highest prophylactically administered dose of R321 reached approximately 70% inhibition of eosinophil recruitment into the airways and, when delivered therapeutically, completely reversed both blood and lung tissue allergen-induced eosinophilia. The inhibitory effect on blood eosinophil counts could be explained by either R321 blocking egress of eosinophils from the bone marrow and/or decreasing eosinophil differentiation. 51 Further studies are warranted, including in severe chronic murine asthma models.
Despite incompletely inhibiting eosinophil recruitment to the airways, R321 delivered at 12 mg/kg fully blocked the development of AHR to methacholine in allergen-challenged mice. AHR is considered a cardinal feature of asthma, and the ability of R321 to completely antagonize the development of AHR in a robust allergic asthma model offers promise of R321 as a therapeutic agent in the treatment of the eosinophilic asthma phenotype. The presence of CCR3 on other non-eosinophil cells relevant to asthma and airway hyperreactivity, such as basophils and subsets of mast cells and T H 2 lymphocytes, could indicate a wider therapeutic effect of R321 beyond inhibition of eosinophil recruitment and activation.
Thus far, drug development has focused on conventional unbiased antagonists, despite growing evidence that chemokine receptors mediate effects both through G protein and non-G protein effectors. An unbiased antagonist of CCR3 acts to inhibit both the activation branch and the desensitization and degradation branch of CCR3 signaling after ligand binding. In this scenario the cell increases its surface receptor density as the basal turnover process continues to produce new receptors. 52, 53 Receptor accumulation might explain the limited in vivo success observed with such unbiased antagonists, such as in a clinical trial in patients with eosinophilic asthma, 48 because eosinophils might eventually overcome inhibition and become resistant.
Our results demonstrate that the novel R321 peptide effectively inhibits G protein-mediated signal transduction by CCR3 but does not interfere with b-arrestin signaling, receptor internalization, and degradation (see Fig E10 in this article' s Online Repository at www.jacionline.org). In contrast, the small-molecule CCR3 antagonists UCB35625 and SB328437 partially or completely block CCR3 internalization, with this effect becoming more pronounced with longer treatment times. Our observation that R321 by itself appears to promote CCR3 internalization without acting as an agonist for chemotaxis suggests the fate of CCR3 internalized in the presence of R321 is biased toward that of degradation instead of cell activation. As demonstrated by using NMR studies, both R321 and CCL11 can bind simultaneously and specifically to the CCR3 receptor, and R321 has 2 independent binding sites. It is possible that R321 binding at a site different than the eotaxin ligand stabilizes a receptor conformation that induces b-arrestin recruitment, although with a much weaker affinity than observed for the eotaxin ligands. Future structural studies should help clarify the unique inhibitory profile of R321.
Avoiding the pitfall of tolerance development by seeking out novel biased antagonists of the CCR3 signaling cascade might hold significant therapeutic promise for eosinophilic asthma, eosinophilic esophagitis, and other eosinophil-associated diseases. Our results should also prove encouraging in a continuing search for biased antagonists of not only CCR3 but also other chemokine receptors and point the way toward approaches other than classical ligand-displacement compounds.
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Key messages
d R321 is a novel biased nanoparticle CCR3 antagonist that inhibits G protein signaling but not b-arrestin-mediated CCR3 internalization and degradation.
d R321 blocks eosinophil recruitment into the blood, lungs, and airways and prevents AHR in a mouse eosinophilic asthma model.
METHODS Peptide synthesis and stock preparation
R321 and R323 were synthesized on a Liberty Blue Microwave peptide synthesizer (CEM Corporation, Matthews, NC) by using Fmoc chemistry and low-loading Rink Amide MBHA resin (Merck, Whitehouse Station, NJ). The following modifications have been introduced to the published protocol of high-efficiency peptide synthesis (http://www.ncbi.nlm.nih.gov/pubmed/ 24456219). Coupling with N,N9-diisopropylcarbodiimide/ethyl 2-cyano-2-(hydroxyimino) acetate was performed for 4 minutes at 908C for all residues except His, for which the reaction was carried out for 10 minutes at 508C. A 5-fold amino acid excess was used on all cycles, and all residues were doublecoupled. All deprotection cycles were conducted at room temperature to avoid racemization and aspartimide formation. Because of the high cost of Fmoc-NH-(PEG) 27 -COOH (Merck), it was attached manually overnight by using 1.2-fold excess and 2-(6-Chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (HCTU) as an activating agent. The peptides were cleaved from the resin and deprotected with a mixture of 90.0% (vol/ vol) trifluoroacetic acid with 2.5% water, 2.5% triisopropyl-silane, 2.5% 2,29-(ethylenedioxy)diethanethiol, and 5% thioanisol. Peptides were purified on a preparative (25 mm 3 250 mm) Atlantis C3 reverse phase column (Agilent Technologies, Santa Clara, Calif) in a 90-minute gradient of 0.1% (vol/ vol) trifluoroacetic acid in water and 0.1% trifluoroacetic acid in acetonitrile, with a 10 mL/min flow rate. Fractions containing peptides were analyzed on an Agilent 6100 LC/MS spectrometer with use of a Zorbax 300SB-C3 PoroShell column and a gradient of 5% acetic acid in water and acetonitrile. Fractions that were more than 95% pure were combined and freeze-dried. Peptide stock solution was prepared by dissolving in dimethyl sulfoxide (DMSO) or DMSOd 6 (for NMR experiments). On reconstitution in PBS (pH 7.2), the final concentration of DMSO was less than 1%. The solutions were sonicated, kept at room temperature overnight, centrifuged, and stored at 2208C.
DLS
Peptides were resuspended in 100% DMSO to a concentration of 1 mmol/L and then further diluted in PBS to a final concentration of 10 mmol/L. The hydrodynamic radius of the peptides was measured on a DynaPro-801 (Protein Solutions, Charlottesville, Va) molecular size detector, and data were analyzed with the provided software by using an aqueous buffer model.
Chemotaxis assays
Optimal concentrations of chemokines (12 nmol/L CCL11, 25 nmol/L CCL24, 100 nmol/L CCL26, and 1 mmol/L PAF) were used to induce cell chemotaxis.
E1,E2 CCL11, CCL24, and CCL26 were purchased from BioLegend, and PAF (C16) was purchased from Tocris Bioscience (Minneapolis, Minn). Inhibitors or controls were placed in both upper and lower chambers of transwell plates with 5-mm pore size membranes (Corning, Kennebunk, Me). For assays used to determine the effect of R321 on chemotaxis of human peripheral blood eosinophils toward PAF, a PAF receptor inhibitor, WEB 2086, was purchased from Tocris Bioscience and used at a concentration of 100 mmol/L as a positive control. A total of 1 3 10 5 cells were placed in each well, and after 4 hours of migration, cells were counted by using flow cytometry (Beckman Quanta SC; Beckman Coulter).
CCL11-induced secretion of ECP
Purified human peripheral blood eosinophils were resuspended in PBS plus 0.1% BSA to a final concentration of 1 3 10 6 cells/mL, and 100 mL was placed in aliquots per well. Cells were pretreated for 30 minutes with 1 mmol/L R321, R323, or vehicle and stimulated with 12 nmol/L CCL11 for 3 hours. After stimulation, cells were centrifuged (1500 rpm for 10 minutes), and supernatants were collected for further analysis. ECP detection in supernatants was performed with a commercial ELISA kit (MesaCup ECP test; MBL, Woburn, Mass).
Detection of ERK1/2 and AKT
AML14.3D10-CCR3 cells were serum starved for 4 hours, resuspended in RPMI 1640 plus 0.1% BSA to a density of 1 3 10 7 cells/mL, and then pretreated with either vehicle control (PBS plus 1% DMSO) or 10 mmol/L inhibitors (R321, R323, SB238437, or UCB35625) for 30 minutes at 378C in a 5% CO 2 atmosphere. Cell aliquots were taken before stimulation and 2.5, 5, 10, 15, and 30 minutes after stimulation with 100 nmol/L CCL11 and washed in ice-cold PBS. Cell pellets were lysed in RIPA lysis buffer (Santa Cruz Biotechnology, Santa Cruz, Calif) containing 1 mmol/L phenylmethylsulfonyl fluoride, 1 mmol/L Na-orthovanadate, 30 mmol/L NaF, and protease inhibitor cocktail tablet (Roche, Indianapolis, Ind). Cell lysate proteins were separated on 12% (wt/vol) SDS-PAGE gels (15 mg per lane) and transferred to polyvinylidene difluoride membranes at 20 V for 40 minutes. Membranes were blocked with 5% BSA for 2 hours at room temperature and incubated overnight at 148C with rabbit anti-phospho-ERK 1/2 antibodies or rabbit anti-phospho-AKT antibodies (Cell Signaling Technology, Danvers, Mass). The next day, membranes were washed extensively and incubated for 1 hour at room temperature with secondary goat anti-rabbit IgGhorseradish peroxidase antibodies (Santa Cruz Biotechnology). Western blots were visualized with SuperSignal West Dura Extended Duration Substrate (Thermo Fisher Scientific, Waltham, Mass). For loading controls, membranes were stripped for 15 minutes in mild stripping buffer (1.5% glycine, 0.1% SDS, and 1% Tween-20, pH 2.2) and reprobed with rabbit anti-ERK1/2 antibodies or rabbit anti-AKT antibodies (Cell Signaling Technology). Three independent experiments were performed.
Gai activation
GTP-bound Gai was detected by using a commercial Gai assay kit (Abcam, Cambridge, Mass) with modifications. Briefly, AML14.3D10-CCR3 cells were serum starved for 16 hours before being pretreated with 200 ng/mL pertussis toxin for 2 hours, 10 mmol/L R321 for 30 minutes, or vehicle control. Pretreated cells were then stimulated with 8 nmol/L CCL11 or medium for 1 minute. The reaction was stopped by adding and washing once in ice-cold PBS. Ten million cells were used for each condition. Washed cells were lysed with 13 lysis buffer, according to the manufacturer's instructions. For pulldown of active Gai, mouse anti-GTP-bound Gai antibody was conjugated to Dynabeads Protein G (Life Technologies, Carlsbad, Calif) for 15 minutes at room temperature. Conjugated beads were washed 3 times with TBS-Tween and incubated with cell lysates for 20 minutes at room temperature. After washing with TBS-Tween, bound proteins were eluted by boiling the beads in 23 SDS sample buffer for 5 minutes. Eluates were resolved by using SDS-PAGE and immunoblotted using a polyclonal rabbit anti-total Gai antibody (Cell Signaling).
CCR3 degradation
AML14.3D10-CCR3 cells were resuspended in RPMI1640 plus 0.1% BSA. Aliquots of 1 3 10 6 cells were pretreated with 10 mmol/L cycloheximide for 1 hour at 378C. Some cells were pretreated concurrently with 10 mmol/L R321 for 30 minutes. Pretreated cells were stimulated with 8 nmol/L CCL11/eotaxin-1 or CCL5/RANTES for 3 hours to induce receptor degradation. Cells were lysed in RIPA buffer and immunoblotted for CCR3 by using a polyclonal rabbit anti-CCR3 antibody (Abcam), followed by goat anti-rabbit IgG-horseradish peroxidase secondary antibody (Santa Cruz Biotechnology).
Immunofluorescence and confocal microscopy AML14.3D10-CCR3 cells were serum starved for 4 hours and then resuspended in RPMI 1640 plus 0.1% BSA to a density of 1 3 10 6 cells/ mL. Cells were pretreated with 10 mmol/L inhibitors (R321, SB238437, or UCB35625) or R323 or vehicle controls for 30 minutes at 378C and then stimulated with 100 nmol/L CCL11. Aliquots were taken before stimulation and 30 minutes after chemokine addition. Cytospin preparations were made by means of centrifugation of the treated cells at 300 rpm (10.16g) for 5 minutes onto glass slides in a cytocentrifuge (Cytospin 2; Shandon, Pittsburgh, Pa). Cells were fixed in ice-cold methanol for 15 minutes at 2208C and washed 3 times in 0.1% Triton X-100 in PBS before blocking in 10% normal goat serum in PBS for 2 hours at room temperature. The slides were incubated overnight at 148C with primary antibodies diluted in 0.1% normal goat serum in PBS. CCR3 was detected with 5 mg/mL mouse anti-human CCR3 antibody (BioLegend) and b-arrestin 2 with rabbit monoclonal anti-human b-arrestin 2 antibody (Cell Signaling Technology).
After extensive washing in 0.1% Tween-20, samples were incubated with appropriate Alexa Fluor 488-or Alexa Fluor 568-conjugated anti-mouse and anti-rabbit secondary antibodies (Cell Signaling Technology) used at 1:500 dilution for 1 hour at room temperature. After washing, coverslips were mounted on the glass slides with SlowFade Gold antifade reagent with 49-6-diamidino-2-phenylindole dihydrochloride (Invitrogen, Carlsbad, Calif). Images were collected with a Zeiss LSM 700 laser scanning confocal microscope and 1003/1.45 oil immersion objective using Zen software (Carl Zeiss AG, Oberkochen, Germany) and further processed with Photoshop CS5 (Adobe, San Jose, Calif).
Quantitative colocalization analysis was performed by selecting single cells as regions of interest (n 5 50 per treatment group) and calculating mean colocalization coefficients by using the Pearson correlation method. Data are presented as means 6 SEMs. Statistical analysis was performed with GraphPad Prism software by using 2-way ANOVA, followed by Tukey post hoc analysis.
Cell-surface staining and gating strategy for mouse blood eosinophils
Mouse blood (900 mL) was collected by means of cardiac puncture into EDTA-coated tubes, and red blood cell lysis was performed through hypotonic shock with H 2 O. White blood cells were washed with PBS and resuspended to 1 3 10 6 cells/100 mL of flow cytometry buffer (PBS plus 0.1% BSA). Inhibition of nonspecific binding to Fc receptors was performed with a rat anti-mouse CD16/CD32 antibody for 5 minutes at room temperature (BD Biosciences, San Jose, Calif). Cells were subsequently stained for 30 minutes at room temperature in the dark with the following antibodies: rat anti-mouse CCR3 fluorescein-conjugated antibody (R&D Systems, Minneapolis, Minn), PE-conjugated rat anti-mouse Siglec-F antibody (BD Biosciences), and rat anti-mouse peridinin-chlorophyll-protein complex-Cyanine 5. 
BAL
One day after the last DRA allergen or sham PBS challenge, mice were killed, and BAL fluid cells were collected by using lavage with 2 mL of cold PBS injected into the trachea through a catheter. Total cell counts were performed with a Countess automated cell counter (Thermo Fisher Scientific). For differential BAL cell counts, cytospin preparations were stained with Wright-Giemsa stain (Sigma-Aldrich, St Louis, Mo). Cells were classified as macrophages, lymphocytes, neutrophils, and eosinophils by using standard morphology and staining. A minimum of 200 cells were counted per slide.
Determination of airway responsiveness to methacholine
Twenty-four hours after the last intranasal challenge, mice were anesthetized and attached to the flexiVent rodent ventilator/pulmonary mechanics analyzer (SCIREQ, Montreal, Quebec, Canada). Baseline respiratory parameters were measured, as previously described. E3 Airway reactivity was assessed by measuring response to increasing doses (0, 5, 10, 20, and 40 mg) of methacholine (Sigma) administered intravenously through the jugular vein.
Reductive methylation of membrane preparations
ChemiSCREEN Chem-1 membrane preparations for recombinant human CCR3 (HTS008M) and negative control (HTS000MC1) CCR3-null membranes were purchased from EMD Millipore (Burlington, Mass). Membrane preparation storage buffer contained 50 mmol/L Tris (pH 7.4), 10% glycerol, and 1% BSA. Glycerol and BSA are important components for the stability and integrity of the membranes; however, BSA and Tris interfere with the reductive methylation reaction. Therefore 13 C formaldehyde (catalog no. 489417; Sigma-Aldrich) and borane-ammonia complex (catalog no. 682098; Sigma-Aldrich) were used in excess to ensure labeling of all possible components of the membranes. On quenching the reaction with excess TrisHCl buffer, membrane fractions were separated by means of ultracentrifugation at 48C, and the membrane pellets were resuspended in PBS containing 10% glycerol and 1% unlabeled BSA. E4 The latter step was repeated to remove residual labeled components.
Reductive methylation of the membrane preparations was performed, as described previously. E5,E6 In brief, 20 mL of 1 mol/L borane-ammonia complex (catalog no. 682098; Sigma-Aldrich) and 40 mL of 1 mol/L 13 C formaldehyde (catalog no. 489417; Sigma-Aldrich) were added to 1 mL of membrane preparation. This mixture was incubated with stirring for 2 hours at 48C. The addition of borane-ammonia and formaldehyde was repeated, and the mixture was incubated with stirring for 2 more hours. The final 10 mL of 1 mol/L borane-ammonia complex was then added, and the mixture was incubated at 48C overnight with stirring. The reaction was then stopped by adding 110 mL of 2 mol/L Tris/HCl (pH 7.6). Thereafter, the membrane preparations were separated by means of ultracentrifugation at 48C and resuspended in PBS containing 10% glycerol and 1% unlabeled BSA to be used for NMR experiments. 
HSQC NMR
13
C decoupling was performed with a GARP sequence. Two hundred fifty-six complex points with 168 scans per Free Induction Decay (FID) were recorded to ensure a 20.9-Hz resolution per point at 900 MHz before zero filling. The relaxation delay was set to 1.5 seconds, and 32 steady-state scans preceded data acquisition. Total collection time was 20 hours.
Data were processed and analyzed with NMRPipe/NMRDraw software.
E7
For dissociation constant determination, data were analyzed by using GraphPad Prism 5 nonlinear regression saturation single binding site equation. Mean values and SDs were calculated based on different fitting approaches (regular fit, robust fit, and automatic outlier). Allergen sensitization/challenge protocol is indicated. Mice were challenged in their airways with DRA allergen or PBS control on days 12 to 14 through intranasal insufflation (black arrows). Treatment with CCR3 R321 peptide nanoparticles, scrambled R323 control peptide, or vehicle was administered prophylactically starting on day 11 before the intranasal allergen challenges on days 11 to 14 (blue arrows; A) or therapeutically starting on day 14 after the last intranasal allergen challenge (red arrows; B). i.p., Intraperitoneal; i.v., intravenous. 
FIG E10.
Schematic of the CCR3 signaling pathway and proposed R321 mechanism of inhibition. A, Agonist receptor binding leads to activation of the G protein-dependent signaling cascade, resulting in eosinophil chemotaxis, secretion, and degranulation. On prolonged exposure to agonist, CCR3 is desensitized and internalized through a b-arrestin-mediated endocytic pathway. B, R321 nanoparticles dissipate on contact with the cell membrane, allowing the R321 peptide monomer to displace the CCR3 TM2 helix. R321 binding alters the CCR3 structure in a manner that inhibits G protein-dependent signaling but not b-arrestin-mediated internalization (endocytosis) and degradation of CCR3.
